Design Therapeutics
DSGN
117 hedge funds and large institutions have $358M invested in Design Therapeutics in 2025 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 39 increasing their positions, 28 reducing their positions, and 8 closing their positions.
4,504% more call options, than puts
Call options by funds: $4.7M | Put options by funds: $102K
288% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 8
39% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 28
38% more capital invested
Capital invested by funds: $260M → $358M (+$98.1M)
23% more funds holding
Funds holding: 95 → 117 (+22)
6.4% more ownership
Funds ownership: 60.57% → 66.97% (+6.4%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$15.9M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
+$12.6M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$7.72M |
| 4 |
Morgan Stanley
New York
|
+$4.12M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$4.07M |
Top Sellers
DSGN Hedge Fund Activity: Q4 2025 in Review
117 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Design Therapeutics (DSGN) for Q4 2025, worth a combined $358M — up 38% from $260M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new DSGN positions and 8 closed out — a net gain of 23 holders — while 39 added to existing stakes and 28 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $15.9M. The largest seller was Tang Capital Management, exiting entirely with an estimated $13.4M sold.
- 117 institutional investors held Design Therapeutics (DSGN) as of Q4 2025, up from 95 in Q3 2025.
- Funds reported $358M of Design Therapeutics stock for Q4 2025, up 38% quarter-over-quarter.
- 31 funds opened new Design Therapeutics positions in Q4 2025 and 8 closed out, a net change of +23 holders.
- The largest Design Therapeutics buyer in Q4 2025 was Point72 Asset Management, an estimated $15.9M added.
- The largest Design Therapeutics seller in Q4 2025 was Tang Capital Management, an estimated $13.4M sold.
Based on aggregated 13F filings for Q4 2025.